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Risk score
48–72 h after CM exposure. Left ventricular function was evaluated in
patients with echocardiography within 24 h before the procedure. PCI
was performed by interventional cardiologists according to standard
clinical practice. Nonionic, low-osmolarity CM was used in all patients.
0.9%Normal saline at a rate of 1mL/kg/hwas administered intravenous-
ly 3–12 h before and 6–12 h after exposure to CM.
The primary end-point was CIN, which was deﬁned as an absolute
increase in SCr of ≥0.5 mg/dL over baseline values within 48–72 h
after CM exposure [5]. The secondary end-points were major adverse
clinical events (MACEs), including all-cause mortality renal replace-Contrast-induced nephropathy (CIN) had been demonstrated to be
associated with short- and long-term adverse outcomes in patients
after percutaneous coronary intervention (PCI) [1–3]. Complex PCI pro-
cedure for coronary chronic total occlusion (CTO) lesions with high risk
of CIN may adversely affect the beneﬁt of the revascularization success,
because of patients with CTO–PCI administrated large contrast medium
(CM), and are generally older and more likely to have reduced ventric-
ular ejection function, and worse renal function than patients without
CTO, which were risk factors of CIN [4].
Identifying patients at high risk of CIN before PCI is of utmost clinical
importance to make timely pre-procedural decisions regarding the
therapeutic intervention to minimizing the risk. Therefore, we aimed
to derive a simple pre-procedural risk score to predict CIN risk in pa-
tients with CTO before PCI.
All consecutive patients with CTO who underwent our institution's
basic PCI protocol between January 2010 and September 2012 were
enrolled prospectively. The study conformed to the ethical principles
laid down in the declaration of Helsinki and the protocol was approved
by our hospital's ethics committee. Written informed consent was
obtained from all patients before the procedure.ning100@126.com (N. Tan).
ork.
land Ltd. This is an open access articlSerum creatinine (SCr) was measured upon admission, and within
ment therapy, acute heart failure, or cerebrovascular events in hospital.
Continuous variables are expressed as mean ± SD and compared
with t-test. Categorical variables are reported as absolute values and/
or percentages and compared byχ2 test or Fisher's exact test. Predictors
of CIN were derived from demographic, clinical, and procedural vari-
ables in the training cohort. Variables with p b 0.20 in the univariate
analysis, together with other known CIN risk factors were entered into
the multivariate logistic regression analysis by forward stepwise
selection to identify independent predictors of CIN. The adjusted odds
ratio (OR) and 95% conﬁdence interval (CI) were calculated. The
model's predictive performance (discrimination) and calibration were
assessed using receiver operating characteristic (ROC) curves and the
calibration slope respectively. All data analyses were performed using
SAS version 9.3. A two-tailed p b 0.05 was always requested for statisti-
cal signiﬁcance.
The total eligible patients (n= 728) were randomized in a 3:2 ratio
to create a training (n= 495) and a validation cohort (n= 233) for risk
score development. Overall, 15 (3.0%) patients developed CIN in train-
ing dataset. Compared to patients without CIN, age ≥ 75 years,
LVEF b 40% and baseline SCr levels of N 1.5 mg/dL were more common
among CIN patients. However, there were no signiﬁcant differences
between the two groups in other demographic, clinical, baseline labora-
tory, and PCI procedure data (Table 1).
Those variables that were signiﬁcant in the univariate analysis, to-
gether with other known risk CIN factors, were included in the multivar-
iate analysis. The results of the latter analysis showed that age≥ 75 years
(OR: 4.43, p=0.011), LVEF b 40% (OR: 3.58, p=0.038) and SCr N 1.5mg/e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline clinical features in patients with and without CIN of the training dataset.
Variable CIN (n = 15) Non-CIN (n = 480) P value
Demographics
Age, (years) 72.0 ± 9.4 62.0 ± 10.7 b0.001
Age ≥ 75 years, (%) 6 (40.0) 61 (12.7) 0.002
Women (%) 3 (20.0) 80 (16.7) 0.108
SBP (mm Hg) 129.4 ± 26.1 128.6 ± 18.6 0.909
DBP (mm Hg) 72.5 ± 10.6 75.8 ± 11.5 0.268
Medical history, n (%)
Smokers 5 (33.3) 211 (44.0) 0.414
Hypertension 10 (66.7) 285 (59.4) 0.571
Diabetes 5 (33.3) 125 (26.0) 0.527
Hypercholesterolemia 2 (13.3) 73 (15.2) 0.842
Prior MI 1 (6.7) 74 (15.4) 0.352
Prior CABG 0 (0.0) 14 (2.9) 0.502
Laboratory ﬁndings
Baseline SCr (μmol/L) 128.0 ± 46.7 88.3 ± 24.9 0.005
Baseline SCr N 1.5 mg/dL, n (%) 6 (40.0) 27 (5.6) b0.001
LVEF% 46.7 ± 14.9 56.1 ± 13.1 0.007
LVEF b 40% 5 (33.3) 53 (12.3) 0.018
HCT 0.38 ± 0.06 0.39 ± 0.05 0.132
Anemia, n (%) 7 (46.7) 166 (34.6) 0.334
Hypoalbuminemia, n (%) 2 (13.3) 73 (15.2) 0.842
Medication, n (%)
Statin 15 (100.0) 469 (97.7) 0.553
ACEI/ARB 13 (86.7) 435 (90.6) 0.607
Calcium channel blocker 4 (26.7) 76 (15.8) 0.262
Procedural characteristic
Contrast volume (mL) 158.7 ± 66.6 155.0 ± 68.7 0.838
Contrast exposure time (min) 108.2 ± 34.7 91.6 ± 47.3 0.178
Number of diseased vessels (n) 3.0 ± 0.9 2.6 ± 0.9 0.050
Number of stents 1.9 ± 1.2 1.9 ± 1.4 0.907
Mehran risk score 10.6 ± 5.2 5.2 ± 3.8 b0.001
Abbreviations: BP: blood pressure; CABG: coronary artery bypass grafting;MI:myocardial
infarction; SCr: serum creatinine; LVEF: left ventricular ejection fraction;HCT: hematocrit;
ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
Mehran risk score: model to deﬁne contrast-induced nephropathy (CIN) by Mehran
et al. Anemia was deﬁned using World Health Organization criteria: baseline hemat-
ocrit value of b39% for men and b36% for women. Hypoalbuminemia was deﬁned as
the serum albumin of b35 g/L.
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CIN. The multivariate model (χ2 = 22.72, p b 0.001;−2LL = 108.40)
had a C-statistic of 0.8. The Hosmer–Lemeshow statistic did not suggest
a lack of ﬁt (degrees of freedom 8, χ2 = 0.195, p = 0.907).Fig. 1.Area under the receiver operating characteristic curve of the present risk score and t
entire cohort (B).Using these three variables as risk indicators for CIN,we developed a
risk scoring system. For this purpose, the beta values from the logistic
model were used, assigning an integer value of 1 for each 1.0 increment
in beta (age ≥ 75 years: 1, LVEF b 40%: 1 and SCr N 1.5 mg/dL: 2). For
each patient, the score was calculated as the sum of the weighted inte-
ger coefﬁcients (range 0–4).
ROC curve analysis showed that the present risk score model had
good predictive value for CIN (C-statistic = 0.789) in the training
dataset. An adequate discriminative power was also demonstrated in
the validation dataset (C-statistic= 0.864). Furthermore, the predictive
accuracy of our risk score for CIN was similar to Mehran score in both
the training (0.789 vs. 0.799, p = 0.866) (Fig. 1A) and total cohort
(0.812 vs. 0.843, p = 0.430) (Fig. 1B)
We further divided the present risk score model into the following
three groups: low risk (score 0, CIN incidence 0), moderate risk
(score = 1, CIN incidence 5.10%), and high risk (score ≥ 2, CIN in-
cidence 19.44%) in training group. Based on this classiﬁcation, the
incidence of CIN in the validation group was 0.97%, 9.76%, 10% in
patients with a low, moderate, and high risk score, respectively.
Both the rate of in-hospital death and MACEs were signiﬁcantly as-
sociated with the low, moderate, and high risk score, respectively
(p b 0.001).
The present study developed a simple pre-procedural risk score,
including only 3 key risk factors, with a good ability for predicting CIN
and in-hospital complications in patients with CTO before PCI.
Several risk scores have been established to predict the risk of CIN
[6–9]. The Mehran risk score was the most widely used and classic
model for CIN.However, itwas established for complete risk assessment
only after CMexposure, which is rather inconvenient in clinical practice.
In addition, precautionary measures could not be adopted and less
individually tailored procedures used in those patients at high risk of
CIN. However, although the present risk score did not include
peri-procedural factors (e.g. CM volume), its predictive value
was similar to Mehran risk score. Apart from its simplicity, the present
risk score is also characterized by a good discriminative ability (C-statis-
tic = 0.789). The use of only three easily calculated variables and the
quick applicability of our CIN risk scores before the procedure, might
render it more clinically attractive, rather than amore elaborate combi-
nation that needs to be calculated by a computer from eight or more
factors [7].
The present study has several limitations. First, it was a prospective,
observational study in a single center, so the inherent weakness cannot
be avoided. Second, the statistical power of the present studymight nothe Mehran risk score for predicting contrast-induced nephropathy in training (A) and
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a single center. The score needs to be conﬁrmed and validated in a large
multicenter trial.
The simple pre-procedural risk score based upon readily available
information including age ≥ 75 years, LVEF b 40% and SCr N 1.5 mg/dL,
but without peri-procedural variables showed excellent predictive abil-
ity for identifying patients with CTO–PCIwho are at high risk of CIN.We
anticipated that this scoring systemmaybeuseful for assisting interven-
tional teams in decision making regarding therapeutic strategies.
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